Autoimmune and inflammatory thyroid diseases following vaccination with SARS-CoV-2 vaccines: from etiopathogenesis to clinical managementArticle Published on 2022-12-012022-11-16 Journal: Endocrine [Category] COVID19(2023년), SARS, 유전자 메커니즘, [키워드] adjuvant adverse effects age Autoimmune autoimmune thyroiditis benefit Clinical management clinician described disease Diseases Doppler Factor Fever Follow-up Genetic genetic susceptibility grave Graves’ disease homology inactivated Inflammatory inflammatory markers men molecular mRNA-based Neck pain palpitation pandemic pathogenic mechanism Patient patients patients with SARS-CoV-2 predisposition Protein reported SARS-CoV-2 SARS-CoV-2 protein SARS-CoV-2 vaccination SARS-CoV-2 vaccines silent Subacute Subacute thyroiditis symptoms onset syndrome Thyroid Thyroiditis Treatment vaccination Vaccine Vaccines. women [DOI] 10.1007/s12020-022-03118-4 PMC 바로가기
Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant RecipientsArticle Published on 2022-11-012022-11-15 Journal: Clinical gastroenterology and hepatology : the off [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] acute respiratory syndrome anti-S anti-SARS-CoV-2 antibody Antibody Response Antibody titer cellular Cellular immune response coronavirus COVID-19 defined domain dose filtration first vaccination HCs healthy control humoral immune response Immunosuppression increase increase in investigated liver liver transplant liver transplant recipients LTR LTRs Lymphocyte count mRNA mRNA-based non-responders Odds ratio Patient Prospective Study RBD recipient responders response risk factor SARS-CoV-2 SARS-CoV-2 vaccination second vaccination Seroconversion seronegative seropositive spike-specific T-cell response T cells the median Third and Fourth SARS-CoV-2 Vaccination. Transplant vaccination Vaccinations [DOI] 10.1016/j.cgh.2022.06.028 PMC 바로가기
Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccinesArticle Published on 2022-11-012022-11-15 Journal: European journal of neurology [Category] SARS, 변종, 진단, [키워드] 95% CI 95% confidence interval Ad26.COV2-S Administered Admission adverse event adverse events adverse events. age analyzed anti-SARS-CoV-2 vaccine BNT162b2 calculated Campylobacter jejuni ChAdOx1 collected CoronaVac COVID-19 diarrhea died dose doses epidemiological Guillain-barrè syndrome immunization inactivated incidence interquartile range Intravenous immunoglobulin male median Mild mRNA-1273 mRNA-based Patient performed plasma positive provided recipient reported risk SARS-CoV-2 Seven Surveillance survivor symptom onset syndrome tested treated vaccination Vaccine Vaccines variant [DOI] 10.1111/ene.15504 PMC 바로가기
Saliva is suitable for SARS-CoV-2 antibodies detection after vaccination: A rapid systematic reviewArticle Published on 2022-09-202022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, 치료기술, [키워드] 95% CI Ad26 analyzed anti-SARS-CoV-2 anti-SARS-CoV-2 vaccination antibodies antibody Antibody detection Antibody titer applied assays AstraZeneca convalescent individual correlation COVID-19 COVID-19 vaccines eligible ELISA assay evaluate flow cytometry highlight IgA IgG Immunity immunoassay Immunoglobulin immunological increasingly infected individuals janssen Johnson & Johnson lack moderate mRNA-based mucosal Neutralizing nine quantification reached reported Saliva Saliva. salivary SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 detection selected serological test serum serum/plasma systematic review vaccinated individual vaccination Vaccination strategy Vaccine Web of Science [DOI] 10.3389/fimmu.2022.1006040 PMC 바로가기
Anti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccinationArticle Published on 2022-08-262022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] antibody booster vaccination CD4 cell Cellular immune response Cohort control group correlated COVID-19 COVID-19 vaccination disease FIVE Follow-up healthy individual HIV HIV-1 Human immunodeficiency virus immune immune response immune responses Immunity immunological immunological non-responder (INR) Immunosuppression immunosuppression. individual lack mRNA-based non-responder Patient receive receiving SARS-CoV-2 SARS-COV-2 infection vaccinated against COVID-19 Vaccine [DOI] 10.3389/fimmu.2022.994173 PMC 바로가기
Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort진행중인 미코페놀레이트 치료는 만성 염증성 자가면역 질환 또는 간 이식 수혜자의 영향을 받는 환자에서 항-SARS-CoV-2 백신 반응을 손상시킵니다: RIVALSA 예상 코호트의 결과Observational Study Published on 2022-08-122022-09-11 Journal: Viruses [Category] SARS, 임상, 진단, 치료기술, [키워드] 95% CI administration Analysis anti-SARS-CoV-2 anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG anti-SARS-CoV-2 vaccination Antibody Response Antibody titers ARMS Arthritis Autoimmune Autoimmune disease Autoimmune diseases Autoimmune hepatitis calcineurin calcineurin inhibitors chronic cohort of patients Complete connective tissue disease Connective tissue diseases detectable develop Diagnosis dose dose reduction Effect effective Eligible patients enrolled evaluate evaluated example first dose healthy subjects hepatology identify IgG immunogenicity immunosuppressive immunosuppressive therapy Immunosuppressive treatment independent predictor independent predictors individual inhibitor liver liver transplant Liver transplantation MMF mRNA COVID-19 vaccine mRNA COVID-19 vaccines mRNA vaccine mRNA-based Multivariate analysis mycophenolate mycophenolate. neoplasia Novara observational study organ other diseases overlapped Patient patients performed predictor Prevent Prospective prospective observational study receiving recipients rejection required response Result rheumatoid arthritis rheumatological SARS-COV-2 infection selected Seroconversion seroconversion failure spondyloarthritis subgroups of patient suffered Suspension Tertiary therapy transplantation transplants treated Treatment unit Univariate analysis university vaccinated individual vaccination Vaccine vaccine response Vasculitis [DOI] 10.3390/v14081766 PMC 바로가기 [Article Type] Observational Study
Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapiesB 세포 고갈 요법을받는 다발성 경화증 환자에서 COVID-19 예방 접종에 대한 강력한 T 세포 활성화Article Published on 2022-08-052022-09-11 Journal: Frontiers in Immunology [Category] SARS, 바이오마커, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive Adaptive immune response Adaptive immunity analyzed anti-CD20 anti-CD20 therapy antibodies antibody production B-cell binding blocking activity BNT162b2 Cellular immune response cellular response Cohort competent Complication condition controls coronavirus COVID-19 COVID-19 vaccination depleting disease driven by form forms hACE2 healthy control humoral Humoral and cellular responses IFNγ IgG antibodies IgG antibody IL-2 immunocompromised individuals Immunotherapy implication individual individuals Infection investigation mRNA mRNA-1273 mRNA-based mRNA-based vaccine multiple sclerosis no difference Ocrelizumab Patient patients proliferation RBD receiving Receptor binding domain recognizing reduced regimen relapsing respiratory rituximab SARS-CoV-2 Seroconversion seroconversion rate severe acute respiratory syndrome Coronavirus significantly significantly higher Spike protein Strong strong T-cell susceptible T-cell T-cell activation T-cell Response therapy vaccination vaccination. Vaccine design virus infection [DOI] 10.3389/fimmu.2022.926318 PMC 바로가기 [Article Type] Article
Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients폐 이식 환자에서 2차 및 3차 SARS-CoV-2 백신에 따른 혈청학적 소견Article Published on 2022-08-012022-09-12 Journal: Immunity, Inflammation and Disease [Category] SARS, 진단, [키워드] acute respiratory syndrome age antibody Antibody titer average BBIBP-CorV booster Booster vaccine ChAdOx1 Clinical data coronavirus coronavirus disease COVID COVID-19 died difference dose doses effective enrolled evaluated had no highest ICU IgG immunization Immunocompromised patients Immunoglobulin Immunological response induce Infection injection intensive care lung transplant median men Messenger RNA mRNA mRNA vaccine mRNA-1273 mRNA-based non-mRNA vaccine pandemic Patient patients positive recipient SARS-CoV-2 SARS-CoV-2 vaccine second dose serology Serum level significantly higher STABLE Support therapy third vaccination Transplant U/mL Vaccine vaccine. was measured were given [DOI] 10.1002/iid3.646 PMC 바로가기 [Article Type] Article
Natural History of Myocardial Injury Following COVID-19 Vaccine Associated MyocarditisResearch article Published on 2022-08-012022-10-05 Journal: The Canadian journal of cardiology [Category] 바이오마커, [키워드] accompanied Acute myocarditis age assessment baseline cardiac changes in Clinical outcome clinical outcomes consecutive patient contractile convalescent COVID-19 COVID-19 vaccination edema Ejection fraction Extracellular fibrosis history improvement IQR Lake LVEF male marker median mRNA mRNA-based myocarditis natural Patient patient cohort performed persistence reduced reduction in reductions in Result Surveillance Symptom threshold tissue inflammation vaccination ventricular Volume were assessed [DOI] 10.1016/j.cjca.2022.07.017 [Article Type] Research article
Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatmentArticle Published on 2022-08-012022-10-05 Journal: ESMO open [Category] 진단, 치료법, [키워드] acute respiratory syndrome anti-spike antibody antibodies baseline BNT162b2 booster booster dose booster vaccination breakthrough infections Cancer cancer patient Cancer patients Care cause CD19+ CD4+ cell counts Cellular immune response cellular immunity cellular response Chemotherapy coronavirus COVID-19 COVID-19 infection died disease dose Efficacy Endocrine evaluated excluded exclusion criteria Factor Factors high risk high-risk population hospital humoral Humoral immunity immune response Immunosuppression immunosuppressive Infection Messenger RNA Mild mRNA mRNA vaccine mRNA-1273 mRNA-based neoplasm neutralizing antibody older patients Other outcome overcome Patient positive reduced required Result severe coronavirus disease significant increase significantly increased significantly lower solid malignancy solid tumors T-cell Response treated Treatment vaccination Vaccine vaccine dose Vaccines were assessed [DOI] 10.1016/j.esmoop.2022.100587 [Article Type] Article